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Objectives: Obesity is a significant risk factor for many liver diseases, including hepatocellular carci-
noma (HCC). Leptin has been identified as a central mediator of factors that regulate energy intake and
expenditure, including appetite, metabolism and fat storage. The role of leptin in the initiation, develop-
ment and progression of HCC remains poorly understood. The aims of this study were to determine the
effect(s) of leptin on HCC cell proliferation and to identify potential signalling mechanism(s) by which leptin
exerts these effects.
Methods: Rat H4IIE HCC cells and H4IIE-derived HCC tumours were analysed for leptin receptor (LR)
expression. H4IIE cells were treated with leptin (0–100 ng/ml) in the absence or presence of pharmaco-
logical inhibitors of p42/p44 mitogen-activated protein kinase (MAPK) (PD98059), p38-MAPK (SB202190)
or Janus kinase-signal transducers and activators of transcription (JAK-STAT) (AG490; 10 mM) signalling.
Cell proliferation was determined and signal pathway activity analysed.
Results: Immunohistochemistry identified increased LR expression in HCC in human tissue. Leptin did
not significantly affect H4IIE cell numbers in serum-depleted (0.1% [v/v] foetal bovine serum [FBS])
medium. However, leptin significantly inhibited serum-stimulated (1.0% [v/v] FBS) H4IIE proliferation.
Immunoblot analysis demonstrated that leptin significantly activated p42/p44-MAPK, p38-MAPK and
STAT3 signalling in a time-dependent manner. Pretreatment of H4IIE cells with SB202190 abrogated
leptin-dependent inhibition of H4IIE proliferation, an effect not observed in cells pretreated with PD98059
or AG490.
Conclusions: Leptin inhibits HCC cell growth in vitro via a p38-MAPK-dependent signalling pathway.
Identifying similar effects on tumour growth in vivomay provide an attractive therapeutic target for slowing
HCC progression.
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Introduction
Hepatocellular carcinoma (HCC) is the most rapidly increasing
type of cancer diagnosed in the USA and represents a major health
burden globally. Common risk factors for HCC development
include chronic alcohol consumption, viral hepatitis infection,
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aflatoxin exposure and obesity.1–3 Obesity is of particular concern
in developed nations because of its rapidly increasing incidence.4
Epidemiological data suggest a strong correlation between obesity
and risk for HCC development; men with a body mass index
(BMI) > 35 are subject to a 4.52-fold increase in relative risk for
HCC.4 Furthermore, risk factors for HCC are noted to act syner-
gistically. For example, patients with hepatitis C virus (HCV)
infection who also abuse alcohol have been reported to have an
approximately 50-fold increased risk for developing HCC.5 Thus,
efforts to reduce obesity and to better understand the mecha-
nism(s) by which obesity contributes to HCC development
and/or progression are of clear clinical significance.
One mechanism by which obesity is proposed to increase risk
for HCC development is described in the ‘two-hit’ theory. In this
model, obesity leads to a fatty liver, steatosis and non-alcoholic
steatohepatitis (NASH). Underlying NASH predisposes the liver
to development of fibrosis, which can, in turn, progress to cirrho-
sis, the leading risk factor for subsequent HCC development.6–9 As
with liver disease, obesity does not develop acutely. Dysregulation
of leptin signalling has been identified as a central factor during
the development of diet-induced obesity. Leptin is a 16-kDa pleio-
tropic hormone involved in a wide range of physiological func-
tions, including thermogenesis, bone formation, pubertal
development, angiogenesis and regulation of satiety.10–13 Under
normal conditions, leptin exerts a cachectic effect whereby it acts
on the brain to suppress appetite and limit food intake.14,15
However, in the setting of obesity the body becomes resistant to
the effects of leptin, resulting in paradoxical weight gain in the
setting of high levels of circulating leptin.16 Leptin signalling
occurs via binding to a specific leptin receptor (LR), a member of
the interleukin-6 receptor family of class 1 cytokine receptors. To
date, six LR isoforms have been reported, each of which contains
an extracellular binding domain. However, only the long form LR
(LRb) also possesses the intracellular domains necessary for signal
transduction.17 Following ligand binding/LRb activation, several
intracellular signalling cascades can be activated, including the
Janus-activated kinase/signal transducers and activators of tran-
scription (JAK/STAT), p38-mitogen/(stress)-activated protein
kinase (p38-MAPK/SAPK) and p42/p44-MAPK extracellular
signal-regulated kinase (ERK) pathways.18,19
Accumulating evidence suggests a potential role for leptin–LR
signalling in the development and/or progression of liver diseases,
including HCC.20–22 In the setting of HCC, leptin is considered to
be important in regulating fat storage and during tumour angio-
genesis.12,22,23 Similarly, a rat model of LR deficiency suggests a link
between leptin signalling and neovascularization in the progres-
sion of NASH to advanced liver injury and tumour formation.24
These experimental data are further supported by pathological
evaluation of human samples in which LR expression correlates
with increased intratumour microvascularity in HCC.25,26
Whereas these data support a role for leptin during tumour
neoangiogenesis, other studies also report that leptin can act as a
mitogen in human HCC cells in vitro.27,28 Despite these data, our
understanding of the mechanisms by which leptin–LR regulates
these events remains poorly defined.
In this study, we analysed the effect of leptin on intracellular
signalling and proliferation using a rat HCC cell line in vitro. Our
findings demonstrate that leptin inhibits serum-stimulated pro-
liferation in the rat H4IIE HCC cell line via a p38-MAPK-
dependent signalling pathway in vitro. Identifying the
mechanism(s) by which leptin signalling acts to alter tumour cell
proliferation is critical to our understanding of the role of obesity
in HCC pathology and provides potential targets for future thera-
peutic intervention.
Materials and methods
Assurances
Institutional review board approval was obtained to collect and
analyse tissue samples from the pathology archives of patients
who had undergone resection for HCC at Carolinas Medical
Center, Charlotte, NC, USA.
Reagents
Minimum essential medium (MEM) and heat-inactivated foetal
bovine serum (FBS) were purchased from Invitrogen, Inc. (Carls-
bad, CA, USA). AG490, SB202190 and PD98059 were purchased
from Sigma-Aldrich Corp. (Saint Louis, MO, USA). Antibodies
against b-actin, ERK 1, STAT3 and LR were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibodies
against p38-MAPK, phospho-p38-MAPK (pp38-MAPK) and
phospho-STAT3 (pSTAT3) were purchased from Cell Signaling
Technology, Inc. (Danvers, MA, USA). An antibody specific
against phospho-ERK 1/2 antibody was purchased from Millipore
Corp. (Billerica, MA, USA). Recombinant rat leptin (rr-leptin)
was purchased from BioVision, Inc. (Mountain View, CA, USA).
Tissue specimens
Paraffin-embedded specimens from 10 patients undergoing
hepatic resection at Carolinas Medical Center were obtained from
pathology archives. An independent pathologist confirmed diag-
nosis, and HCC and adjacent non-tumour liver (NTL) were
marked. Representative tissue sections were used for subsequent
immunohistochemical study.
Cell culture and treatments
The rat H4IIE hepatoma cell line was obtained from the American
Type Culture Collection (ATCC) (Manassas, VA, USA) and main-
tained in MEM supplemented with 10% (v/v) FBS as previously
reported.29 When cells were 70–80% confluent, culture medium
was replaced with low serum (0.1% v/v FBS) for 24 h prior to
experimentation. To determine the effect of leptin on intracellular
signalling, cells were treated with 100 ng/ml leptin or vehicle
(dimethyl sulphoxide [DMSO] 0.1% [v/v]) for up to 24 h. In a
parallel series, cells were pretreated for 1 h with one of AG490
(STAT3 inhibitor, 10 mM), PD098059 (p42/p44 ERK inhibitor,
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10 mM), SB202190 (p38-MAPK inhibitor, 100 nm) or vehicle
(0.1% [v/v] DMSO) prior to leptin addition.
To determine the effect of leptin on cell proliferation, H4IIE
cells were treated with 100 ng/ml leptin for 1 h prior to the addi-
tion of either 0.1% (v/v) FBS (low-serum medium [LSM]) or
1.0% (v/v) FBS. Culture medium was subsequently aspirated and
replaced with fresh leptin-containing culture medium (0.1% or
1.0% [v/v] FBS accordingly) every 24 h. To evaluate the role of
intracellular signal pathway inhibitors on the effect of leptin on
HCC cell proliferation, AG490 (10 mM), PD098059 (10 mM),
SB202190 (100 nm) or vehicle (0.1% [v/v] DMSO) were added
1 h prior to the addition of leptin and replaced daily along with
culture medium and leptin. Cell numbers and viability at 24-h
intervals were established using a Countess Automated Cell
Counter (Invitrogen, Inc.).
Western blot analysis
Following treatment, cells were washed with ice-cold phosphate-
buffered saline (PBS) and whole-cell lysates prepared using radio-
immunoprecipitation assay buffer (1.0% [v/v] NP-40, 0.5% [v/v]
deoxycholate, 0.1% [w/v] sodium dodecyl sulphate [SDS],
0.5 mM phenylmethylsulphonyl fluoride, 0.05 mM Na3V04,
2 mg/ml aprotinin in PBS). Protein concentrations were deter-
mined using a 660-nm Protein Assay (Thermo Fisher Scientific,
Inc., Rockford, IL, USA) according to the manufacturer’s specifi-
cations. Western blot analysis and detection were performed as
previously reported.30 Primary antibodies were diluted 1:1000
with the exception of anti-LR (1:500) in 5.0% (v/v) non-fat dry
milk diluted in Tris-Tween 20 buffered saline (NFDM-TTBS) and
incubated overnight at 4 °C. Secondary antibodies were diluted
1:5000 in 5.0% NFDM-TTBS for 1 h at room temperature.30
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was sectioned (4 mM),
dried onto glass slides and processed for immunohistochemistry
as previously reported.31 Tissue was probed using the anti-LR
antibody (1:50 dilution, overnight at 4°C). Immunodetection was
performed using an avidin-biotin complex system as per the
manufacturer’s instructions (Santa Cruz Biotechnology, Inc.).
Slides were counterstained with Mayer’s haematoxylin, dehy-
drated through graded alcohols and mounted with a coverslip.
Slides were scored by two blinded, independent investigators and
the average of these scores used for subsequent statistical analysis.
Statistical analysis
In vitro experiments were performed a minimum of three times.
Data are expressed as mean standard error of the mean (SEM).
Statistical analysis was performed using one-wayanovawith Dun-
nett’s post-test. A P-value of < 0.05 was considered significant.
Results
Leptin receptor expression in HCC
Immunohistochemistry was performed to detect LR expression in
human HCC specimens and adjacent NTL (Fig. 1A). There was
significantly higher staining for LR in the tumour mass compared
with NTL (2.26  0.27 and 0.08  0.06, respectively, n = 10; P <
0.001) (Fig. 1B). We next performed Western blot analysis for LR
expression in whole-cell lysates prepared from cultured H4IIE
cells. These data demonstrate two major bands at 90 kDa and
120 kDa corresponding to the long and short forms of the LR
(Fig. 1C) and as previously reported by others.27
Leptin inhibits serum-induced H4IIE proliferation
Cell proliferation was measured for H4IIE cells cultured in 0.1%
(v/v) FBS culture medium (LSM) or 1.0% (v/v) FBS with or
without leptin pretreatment (100 ng/ml, 1 h prior to FBS addi-
tion). In cells maintained in LSM, treatment with leptin failed to
significantly alter cell numbers at any point in the 4-day experi-
mental period, an effect not significantly different to that mea-
sured in untreated cells (Fig. 2) (n = 6 independent experiments
performed in duplicate). By contrast, leptin pretreatment signifi-
cantly delayed 1.0% (v/v) FBS-stimulated cell proliferation up
to 72 h post-FBS stimulation (P < 0.05 for leptin + FBS
vs. FBS alone, n = 6 independent experiments performed in
duplicate) (Fig. 2). However, by 96 h the inhibitory effect of
leptin was exhausted and cell proliferation of leptin-pretreated
cells did not significantly differ from that of FBS-only treated
cells (n = 6 independent experiments performed in duplicate)
(Fig. 2).
Leptin stimulates STAT3, ERK and p38-MAPK activity
in H4IIE cells
To gain understanding of the mechanism(s) by which leptin
affects H4IIE cell proliferation, we examined the effect of leptin on
downstream intracellular signalling cascades. Quiescent H4IIE
cells were first treated with leptin (100 ng/ml), after which total
and activated STAT3 (STAT3/pSTAT3), p42/p44 ERK-MAPK
(ERK 1/pERK 1/2) and p38-MAPK (p38-MAPK/pp38-MAPK)
were measured. The results demonstrated that leptin significantly
stimulated activation of all three signalling cascades, albeit with
different kinetic profiles. STAT3 activation occurred within
20 min and was sustained for the next 2–4 h before decreasing
toward baseline activity at 8–24 h (n = 3 independent experi-
ments) (Fig. 3A). Conversely, p42/p44 ERK-MAPK and p38-
MAPK remained largely unchanged for the first 1–2 h before
increasing over the remainder of the experimental time course
(4–24 h, n = 3 independent experiments) (Fig. 3B, C).
To confirm the specificity of pharmacological inhibitors, we
performed a parallel series of experiments in which cells were
pretreated (1 h) with a selective inhibitor of JAK-STAT (AG490,
10 mM), p42/p44 ERK-MAPK (PD98059, 10 mM) or p38-MAPK
(SB202190, 100 nm) signalling prior to leptin treatment. These
data demonstrated inhibition of the respective signalling path-
ways using time-points previously established for leptin-
dependent activation (Fig. 4A–C).
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Figure 1 Leptin receptor expression in human and animal models of hepatocellular carcinoma (HCC). (A) Representative immunohistochemi-
cal micrographs of leptin receptor (LR) staining (arrows) in human non-tumour liver (NTL) and HCC specimens. (B) Cumulative scoring
analysis of LR expression in human NTL and HCC specimens expressed as mean histological score (arbitrary units [AU]; values are mean
 standard error of the mean of five separate fields, independently blind-scored by two different investigators, n = 10; *P < 0.001).
(C) Representative Western blot analysis of samples prepared from cultured H4IIE cells culture using an antibody specific against LR at
1:500 and 1:1000 dilutions
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Figure 2 Leptin (L) inhibits serum-stimulated H4IIE cell proliferation in vitro. H4IIE hepatocellular carcinoma cells were cultured in medium
containing either 0.1% (v/v) foetal bovine serum (FBS) (LSM) or 1.0% (v/v) FBS in the absence or presence of leptin (L, 100 ng/ml). Number
of cells was calculated as a fold change vs. number of cells at day 0, n = 6 separate experiments; *P < 0.05 1.0% (v/v) FBS + L vs. 1.0%
(v/v) FBS
228 HPB
HPB 2011, 13, 225–233 © 2011 International Hepato-Pancreato-Biliary Association
Leptin inhibition of H4IIE proliferation is
p38-MAPK-dependent
To determine the role of specific signalling pathways in leptin-
mediated inhibition of H4IIE proliferation, we next pretreated
quiescent H4IIE cells with AG490 (10 mM), PD98059 (10 mM) or
SB202190 (100 nm) followed by leptin (100 ng/ml, 1 h). Cells
were then stimulated with 1.0% FBS (v/v) and sequential cell
counts performed at 24 h, 48 h and 72 h. As previously, FBS
alone stimulated cell proliferation and this effect was signifi-
cantly inhibited by leptin pretreatment (P < 0.05 for 1.0% [v/v]
FBS vs. LSM; P < 0.05 for leptin + FBS vs. FBS; n = 4 indepen-
dent experiments) (Fig. 5A). Pretreatment of cells with AG490 (a
JAK-STAT inhibitor) abrogated FBS-stimulated cell prolifera-
tion, in both the absence and presence of leptin (n = 4 indepen-
dent experiments) (Fig. 4). Similarly, PD98059 significantly
inhibited FBS-stimulated proliferation compared with FBS
alone, and this effect was not significantly affected by leptin
pretreatment (n = 4 independent experiments) (Fig. 5B).
Conversely, inhibition of p38-MAPK (SB202190) did not signifi-
cantly affect FBS only-stimulated proliferation over the first 48 h
(Fig. 4). However, pretreatment with SB202190 abrogated the
inhibitory effect of leptin on FBS-dependent proliferation to a
level not significantly different from that in cells treated with
SB202190 and FBS (n = 4 independent experiments) (Fig. 5C).
Pretreatment of cells with drug vehicle (0.1% [v/v] DMSO) did
not significantly affect FBS-stimulated proliferation or leptin +
FBS-stimulated proliferation at any of the time-points assayed
(data not shown).
Discussion
From a global perspective, the leading risk factor for HCC devel-
opment remains chronic viral hepatitis infection. Despite a global
decline in the incidence of hepatitis B virus (HBV), the incidence
of HCC is rapidly increasing in developed nations and the most
common risk factor is chronic alcohol abuse. However, obesity is
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Figure 3 Leptin stimulates STAT3, extracellular signal-regulated kinase (ERK) and p38-MAPK activation in H4IIE cells in vitro. H4IIE
hepatocellular carcinoma cells were cultured in medium containing 0.1% (v/v) foetal bovine serum (FBS) and treated in with leptin (100 ng/ml)
for 0–24 h. Whole-cell extracts were analysed by Western blot using antibodies against (A) STAT3/pSTAT3, (B) pERK 1/2/ERK 1 or (C)
p38-MAPK/pp38-MAPK. In all experiments membranes were stripped and probed with an antibody against b-actin as a housekeeping
protein. Bands were analysed by optical integrated volume in arbitrary units (AU) and data expressed as a ratio of activated : total protein.
n = 3 separate experiments; *P < 0.05 vs. untreated cells
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reaching epidemic proportions in the USA and other developed
countries.32 Obesity is a risk factor for a variety of cancers, includ-
ing endometrial and breast cancer in women, and pancreatic
cancer in both men and women.4,33 Further, a strong association
between obesity and risk for HCC has been identified, particularly
in males. Interestingly, these data indicate that obesity acts syner-
gistically with HCV and insulin resistance, yet not with HBV.34,35
Despite these epidemiological data, our mechanistic understand-
ing of how obesity contributes to HCC development and/or pro-
gression is limited.
Under normal physiological conditions, leptin regulates appe-
tite by acting on the hypothalamus. However, in the setting of
obesity, leptin levels rise in correlation with BMI as a result of
central leptin resistance and the suppressive effects of leptin on
appetite are lost. This has led to the hypothesis that high levels of
leptin in obese patients may contribute to the initiation and/or
progression of various cancers. In vitro studies utilizing cholan-
giocarcinoma,36 breast,37 endometrial38 and HCC27,28 cancer cell
lines report that leptin is a mitogen. Conversely, leptin was shown
to be growth-inhibitory in pancreatic cancer cells39 and cells
derived from a colon carcinoma.40 In the current study, leptin
treatment of a rat HCC cell line demonstrated leptin inhibition
of serum-stimulated proliferation. This finding contrasts with
those of other studies in which leptin promoted human HCC cell
line proliferation. In addressing these differences, several distinc-
tions become evident between the studies. Saxena et al.27 utilized
the HepG2 human hepatoblastoma cell line, whereas Ramani
et al.28 used the HuH7 and HepG2 cell lines. Thus species- and
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Figure 4 Pharmacological inhibitors alter leptin-dependent signal
transduction in H4IIE cells in vitro. H4IIE hepatocellular carcinoma
cells were cultured in medium containing 0.1% (v/v) foetal bovine
serum (FBS) and treated with one of AG490 (AG; STAT3 inhibitor,
10 mM), PD098059 (PD; pERK1/2 inhibitor, 10 mM), SB202190 (SB;
p38-MAPK inhibitor, 100 nm), leptin (L; 100 ng/ml) or inhibitor (1 h)
followed by leptin (100 ng/ml). Whole-cell extracts were analysed by
Western blot using antibodies against (A) STAT3/pSTAT3, (B) pERK
1/2/ERK 1 or (C) p38-MAPK/pp38-MAPK. C, control
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Figure 5 Inhibition of p38-MAPK signalling abrogates leptin-mediated inhibition of H4IIE cell proliferation in vitro. H4IIE hepatocellular
carcinoma cells were cultured in medium containing one of 0.1% (v/v) foetal bovine serum (FBS) (low-serum medium [LSM]), LSM + leptin
(L; 100 ng/ml), LSM + inhibitor (AG490 [AG]; STAT3 inhibitor, 10 mM), PD098059 (PD; pERK1/2 inhibitor, 10 mM), SB202190 (SB; p38-MAPK
inhibitor, 100 nm) or inhibitor + leptin. Number of cells was calculated as fold change vs. number of cells at day 0. n = 4 separate
experiments; *P < 0.05 vs. 24-h C; †P < 0.05 vs. 48-h C; ‡P < 0.05 vs. 72-h C. C, control
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tumour-specific variation may explain the differences in response
to leptin in vitro. This distinction may be particularly important
when comparing results obtained with serum-depleted media to
examine the potential mitogenic effects of leptin. In both the
Saxena et al.27 and Ramani et al.28 studies, in which leptin stimu-
lated proliferation, cells were exposed to leptin in serum-depleted
culture medium. That is, the cells in these studies were quiescent
and leptin was the only exogenous agent added. By contrast,
leptin failed to stimulate H4IIE cells to proliferate under the
same conditions in our study. However, when H4IIE cells were
induced to proliferate with FBS, leptin acted to significantly
inhibit serum-stimulated, cycling cell proliferation. These
data suggest that the inhibitory effects of leptin may be cell
cycle-dependent.
Although our data demonstrate the inhibition of serum-
stimulated growth by leptin, it is also of interest to note that, after
96 h, leptin appeared unable to continue inhibiting serum-
stimulated growth and cell numbers were approximately equal at
this time-point. One possible explanation for this observation is
that, by 96 h, the FBS-stimulated cells had reached confluence and
no additional proliferation was observed (i.e. the growth curve
reached a plateau; data not shown). Although contact inhibition
of growth explains why FBS-only stimulated cells do not continue
to grow, it does not explain why cells pretreated with leptin start to
proliferate again after 72–96 h. One possible explanation for this
may refer to the clinical paradox whereby obese patients exhibit
elevated circulating leptin levels although leptin normally acts to
suppress appetite. Using disease models, it has been demonstrated
that continued exposure to high circulating leptin leads to a cor-
responding downregulation of LR expression. In this setting a
positive feedback loop exists whereby increased leptin production
occurs as a result of the lack of effect caused by diminished recep-
tor expression. A similar series of events may have occurred in our
experimental setting whereby continued exposure to high levels of
leptin in the culture medium (leptin was replaced every 24 h along
with fresh FBS medium) leads to downregulation or internaliza-
tion of the LR.
Although changes in LR expression may be of importance in
longterm response to circulating leptin, differences in how leptin
signals are transduced within the cell may be equally important. In
studies using human HCC cells, and the current study, leptin
significantly stimulated STAT3 activation. Conversely, leptin failed
to significantly stimulate p42/p44 ERK phosphorylation in H4IIE
cells. This finding may be equally important to our understanding
of the differences observed in these studies as leptin-dependent
proliferation in both HepG2 and HuH7 cells required activation
of p42/p44 ERK signalling.27 Indeed, previous reports by our
group have demonstrated the central role of p42/p44 ERK in
mediating a range of receptor-mediated proliferation in both
human and animal models of HCC.41,42
In our experimental model, p42/p44 ERK appears to be less
relevant in mediating the effects of leptin, but the opposite is true
for p38-MAPK-dependent signalling. That is, pretreatment of
H4IIE cells with SB202190 (a p38-MAPK specific inhibitor)
reversed the inhibition of proliferation by leptin for up to 48 h.
Previous studies report that p38-MAPK exerts growth-inhibitory
effects by suppressing cyclin D1 expression.43,44 Saxena et al.27 did
not investigate the potential involvement of p38-MAPK signalling
in leptin-mediated HepG2 and Huh7 proliferation, and further
investigation is required to ascertain whether a role for this
pathway exists in these cells.
Canonical leptin-signalling occurs via LR-mediated activation
of JAK/STAT. In response to the activation of STAT, upregulation
of suppressor of cytokine signalling (SOCS) family members
occurs. SOCS3 prevents phosphorylation of JAK2, which, in
turn, prevents the further phosphorylation/activation of
STAT3.45 Leptin has been demonstrated to upregulate SOCS3
expression, a critical component in establishing central leptin
resistance.46 Given that STAT3 phosphorylation in leptin-treated
H4IIE cells is only transiently elevated, SOCS3 may play a role in
attenuating STAT3 phosphorylation and, in part, explain how
leptin fails to stimulate proliferation in H4IIE cells, yet promotes
proliferation in HepG2 and HuH7 cells. Inhibition of the JAK/
STAT/ERK axis by SOCS3 may enhance the proliferation-
inhibiting effects of p38-MAPK on leptin-treated H4IIE cells.
SOCS3 has also been suggested as a potential suppressor of HCC
tumours as deletion of hepatic SOCS3 promotes diethyl
nitrosamine-mediated tumour formation in mice.47 However,
the role of SOCS3 remains somewhat ambiguous as examination
of HCC sections showed that SOCS3 expression was associated
with higher tumour grade and, in a subset of patients with vas-
cular invasion, high SOCS3 expression correlated with decreased
survival.48
The data from our study suggest that leptin might exhibit
similar antimitogenic effects in HCC cells in vivo, when cells are
exposed to a full complement of cytokines and growth factors.
However, any discussion of the role of leptin in vivo must con-
sider other factors. Previous studies have reported the require-
ment of neovascularization in a model of NASH progression to
HCC via a vascular endothelial growth factor (VEGF)-
dependent mechanism.24 Furthermore, leptin has been reported
to promote angiogenesis in vivo in a chick embryo chorioallan-
toic membrane assay.22 Similarly, increased LR expression has
been reported in human HCC, and that LR expression is
strongly localized to vascular endothelial cells within the
tumour. This has led to speculation that leptin–LR signalling
may be a central factor in mediating the neovascularization
required for tumour progression in vivo effects that would
promote tumorigenesis, particularly if LR expression is down-
regulated in HCC in the setting of continued high circulating
leptin levels (i.e. obesity).
In conclusion, our data demonstrate that leptin inhibits prolif-
eration of H4IIE HCC cells in vitro and this effect is caused, at
least in part, by a p38-MAPK-dependent mechanism. These find-
ings, when taken in parallel with those of other studies, typify the
diverse nature of HCC and underscore the challenges involved in
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elucidating common mechanisms in the initiation and progres-
sion of HCC in humans.
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